Antibodies targeting CTLA-4 and PD-1, B7 family co-inhibitory receptors, have elicited durable clinical outcomes in previously refractory cancer types and are considered a breakthrough in cancer therapy [41]. The gene discussed is PDCD1; the disease is cancer.